(Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains

Biomedical and Life Sciences

Text available via DOI:

https://doi.org/10.1016/j.ejphar.2011.11.005
Final published version

Keywords

Animals, Brain, Gene Expression Regulation, Glucagon-Like Peptide 1, Learning, Male, Maze Learning, Memory, Phosphoproteins, Phosphorylation, Rats, Rats, Wistar, Spatial Behavior, Streptozocin, tau Proteins

View graph of relations

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

(Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. / Li, Lin; Zhang, Zhi-Feng; Hölscher, Christian et al.
In: European Journal of Pharmacology, Vol. 674, No. 2-3, 15.01.2012, p. 280-286.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Bibtex

@article{f6e8748c97f442798fbf4fb87ed7fcd8,

title = "(Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains",

abstract = "It has being shown that glucagon-like peptide-1 (GLP-1), a new anti-diabetes agent, significantly attenuated beta-amyloid (Aβ) levels in rats. In the present study, (Val(8))GLP-1 was used to prevent impairments in memory formation, tau hyperphosphorylation and ultra-structural changes induced by streptozotocin intracerebroventricular (i.c.v.) injection. A spatial water maze task was used to test the rats' learning and memory formation, Western blot was used to measure tau hyperphosphorylation/total tau, and transmission electron microscope was used to find ultra-structural changes. The results shown that streptozotocin induced a series of Alzheimer disease -like changes in behaviour, a significant decline in learning and memory formation, an increased expression of total tau and an increased ratio of phosphorylated tau, and damage to nucleus and nucleolus as seen in electron micrographs. After treatment with (Val(8))GLP-1 (50 μM in 10 μl i.c.v.), there is a significant improvement in learning and memory, a reduction in total tau expression and hyperphosphorylated tau levels, and a recovery of damaged cell nuclei and nucleolus. Our results indicated that (Val(8))GLP-1 might prevent age-related neurodegenerative changes by preventing decline of learning and memory formation, reduction of phosphorylated tau levels and protection of subcellular structures and morphology of neurons. Therefore, (Val(8))GLP-1 is potentially a novel treatment for Alzheimer's disease.",

keywords = "Animals, Brain, Gene Expression Regulation, Glucagon-Like Peptide 1, Learning, Male, Maze Learning, Memory, Phosphoproteins, Phosphorylation, Rats, Rats, Wistar, Spatial Behavior, Streptozocin, tau Proteins",

author = "Lin Li and Zhi-Feng Zhang and Christian H{\"o}lscher and Chong Gao and Yuan-Hong Jiang and Yue-Ze Liu",

year = "2012",

month = jan,

day = "15",

doi = "10.1016/j.ejphar.2011.11.005",

language = "English",

volume = "674",

pages = "280--286",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier",

number = "2-3",

}

RIS

TY - JOUR

T1 - (Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains

AU - Li, Lin

AU - Zhang, Zhi-Feng

AU - Hölscher, Christian

AU - Gao, Chong

AU - Jiang, Yuan-Hong

AU - Liu, Yue-Ze

PY - 2012/1/15

Y1 - 2012/1/15

N2 - It has being shown that glucagon-like peptide-1 (GLP-1), a new anti-diabetes agent, significantly attenuated beta-amyloid (Aβ) levels in rats. In the present study, (Val(8))GLP-1 was used to prevent impairments in memory formation, tau hyperphosphorylation and ultra-structural changes induced by streptozotocin intracerebroventricular (i.c.v.) injection. A spatial water maze task was used to test the rats' learning and memory formation, Western blot was used to measure tau hyperphosphorylation/total tau, and transmission electron microscope was used to find ultra-structural changes. The results shown that streptozotocin induced a series of Alzheimer disease -like changes in behaviour, a significant decline in learning and memory formation, an increased expression of total tau and an increased ratio of phosphorylated tau, and damage to nucleus and nucleolus as seen in electron micrographs. After treatment with (Val(8))GLP-1 (50 μM in 10 μl i.c.v.), there is a significant improvement in learning and memory, a reduction in total tau expression and hyperphosphorylated tau levels, and a recovery of damaged cell nuclei and nucleolus. Our results indicated that (Val(8))GLP-1 might prevent age-related neurodegenerative changes by preventing decline of learning and memory formation, reduction of phosphorylated tau levels and protection of subcellular structures and morphology of neurons. Therefore, (Val(8))GLP-1 is potentially a novel treatment for Alzheimer's disease.

AB - It has being shown that glucagon-like peptide-1 (GLP-1), a new anti-diabetes agent, significantly attenuated beta-amyloid (Aβ) levels in rats. In the present study, (Val(8))GLP-1 was used to prevent impairments in memory formation, tau hyperphosphorylation and ultra-structural changes induced by streptozotocin intracerebroventricular (i.c.v.) injection. A spatial water maze task was used to test the rats' learning and memory formation, Western blot was used to measure tau hyperphosphorylation/total tau, and transmission electron microscope was used to find ultra-structural changes. The results shown that streptozotocin induced a series of Alzheimer disease -like changes in behaviour, a significant decline in learning and memory formation, an increased expression of total tau and an increased ratio of phosphorylated tau, and damage to nucleus and nucleolus as seen in electron micrographs. After treatment with (Val(8))GLP-1 (50 μM in 10 μl i.c.v.), there is a significant improvement in learning and memory, a reduction in total tau expression and hyperphosphorylated tau levels, and a recovery of damaged cell nuclei and nucleolus. Our results indicated that (Val(8))GLP-1 might prevent age-related neurodegenerative changes by preventing decline of learning and memory formation, reduction of phosphorylated tau levels and protection of subcellular structures and morphology of neurons. Therefore, (Val(8))GLP-1 is potentially a novel treatment for Alzheimer's disease.

KW - Animals

KW - Brain

KW - Gene Expression Regulation

KW - Glucagon-Like Peptide 1

KW - Learning

KW - Male

KW - Maze Learning

KW - Memory

KW - Phosphoproteins

KW - Phosphorylation

KW - Rats

KW - Rats, Wistar

KW - Spatial Behavior

KW - Streptozocin

KW - tau Proteins

U2 - 10.1016/j.ejphar.2011.11.005

DO - 10.1016/j.ejphar.2011.11.005

M3 - Journal article

C2 - 22115895

VL - 674

SP - 280

EP - 286

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -

Research

Links

Text available via DOI:

Keywords